.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 9,206,217

« Back to Dashboard

Details for Patent: 9,206,217

Title:Nucleoside phosphoramidates
Abstract: Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent 5 RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals.
Inventor(s): Ross; Bruce (El Granada, CA), Sofia; Michael Joseph (Doylestown, PA), Pamulapati; Ganapati Reddy (San Ramon, CA), Rachakonda; Suguna (Twinsburg, OH), Zhang; Hai-Ren (San Jose, CA), Chun; Byoung-Kwon (Robbinsville, NJ), Wang; Peiyuan (Totowa, NJ)
Assignee: Gilead Pharmasset LLC (Foster City, CA)
Filing Date:Jan 02, 2013
Application Number:13/732,725
Claims:1. cited by applicant .
Claims of U.S. Appl. No. 12/783,680 as filed May 20, 2010. cited by applicant .
Claims of U.S. Appl. No. 13/099,671 as filed Sep. 4, 2012. cited by applicant .
Claims of U.S. Appl. No. 13/956,195 as amendment Oct. 21, 2013. cited by applicant .
Claims of U.S. Appl. No. 14/013,237 as amended Aug. 30, 2013. cited by applicant .
Claims of U.S. Appl. No. 14/057,675 as amended Oct. 22, 2013. cited by applicant .
Communication enclosing Partial European Search Report for European Patent Application No. 13159791.6 dated Feb. 6, 2014 (6 pages). cited by applicant .
Communication pursuant to Rule 114(2) for European Application No. 11714465.9 dated Dec. 1, 2014 (3 pages). cited by applicant .
Engish Translation of Office Action for Taiwanese Application No. 100111246 dated Sep. 15, 2014 (3 pages). cited by applicant .
English Translation for Office Action in Korean Application No. 10-2014-7032628 dated Feb. 6, 2015 (8 pages). cited by applicant .
English Translation of Office Action for Chilean Application No. 716-2011 dated Oct. 9, 2014 (8 pages). cited by applicant .
English Translation of Office Action for Eurasian Application No. 201290993 dated Sep. 17, 2014 (3 pages). cited by applicant .
English Translation of Office Action for Mexican Application No. MX/a/2012/011171 dated Aug. 7, 2014 (3 pages). cited by applicant .
English Translation of Office Action for Panamanian Application No. 89230-02 dated Jun. 17, 2014 (4 pages). cited by applicant .
English Translation of Office Action in Chilean Application No. 903-13 dated Dec. 3, 2014 (8 pages). cited by applicant .
English translation of Office Action in Japan Application No. 2012-512043 dated Mar. 17, 2015 (8 pages). cited by applicant .
English translation of Office Action in Japanese Application No. 2013-502843 dated Feb. 19, 2015 (3 pages). cited by applicant .
English Translation of Office Action in Korean Application No. 10-2011-7030501 dated Mar. 25, 2015 (4 pages). cited by applicant .
Examination Report for New Zealand Application No. 603232 dated Dec. 4, 2014 (3 pages). cited by applicant .
Examination Report in Australia Application No. 2011235112 dated Feb. 5, 2015 (3 pages). cited by applicant .
Grakoui et al., "Characterization of the Hepatitis C Virus-Encoded Serine Proteinase: Determination of Proteinase- Dependent Polyprotein Clevage Sites," J. Virol., (1993), 67(5):2832-2843. cited by applicant .
Griffith et al., "HCV Anti-viral Agents," Annual Reports in Medicinal Chemistry, (2004), 39:223-237. cited by applicant .
International Search Report and Written Opinion mailed Jun. 15, 2006 for International Application No. PCT/US05/25916. cited by applicant .
International Search Report and Written Opinion mailed Nov. 7, 2011 for International Patent Application No. PCT/US2011/030725. cited by applicant .
Written Opinion in Internation Application No. PCT/EP2006/069060 mailed Jan. 30, 2007. cited by applicant .
Written Opinion in Internation Application No. PCT/US2005/032406 mailed May 8, 2008. cited by applicant .
Written Opinion in Internation Application No. PCT/US2010/035641 mailed Sep. 28, 2010. cited by applicant .
Koonin, et al., "Evolution and Taxonomy of Positive-Strand RNA Viruses: Implications of Comparatives Analysis of Amino Acid Sequences," Crir. Rev. Biochem. Malec. Biol. 1993, 28, 375-430. cited by applicant .
Lalezari, J., et al., "Once Daily PSI-7977 Plus PegIFN/RBV in a Phase 28 Trial: Rapid Virologic Suppression in Treatment-Naive Patients with HGV GT2/GT3," J. Hepatology (2011) 54:S28 (Abstract #61 ). cited by applicant .
Lam, Angela M., et al., "PSI-7851, a Pronucleotide of beta-D-2'-Deoxy-2'-Fluoro-2'-C-Methyluridine Monophosphate, Is a Potent and Pan-Genotype Inhibitor of Hepatitis C Virus Replication," Antimicrob. Agents & Chemother. (2010) 54 (8):3187-3196. cited by applicant .
Lawitz, E., et al., "Once Daily Dual-Nucleotide Combination of PSI-938 and PSI-7977 Provides 94% HGV RNA <Lod at Day 14: First Purine/Pyrimidine Clinical Combination Data (the Nuclear Study)," J. Hepatology (2011) 54:S543 (Abstract #1370). cited by applicant .
McGuigan et al., Bioorg & Med. Chem. (1999), 42(3):393-399. cited by applicant .
McGuigan et al., Bioorg. & Med. Chem. Lett., (2010), 20:4850-4854. cited by applicant .
Murakami, Eisuke, et al., "Mechanism of Activation of PSI-7851 and Its Diastereoisomer PSI-7977," J. Biol. Chem., (2010), 285(45):34337-34347. cited by applicant .
Office Action for Pakistani Application No. 233/2011 dated Mar. 28, 2014 (2 pages). cited by applicant .
Office Action for Pakistani Application No. 748/2012 dated Sep. 4, 2014 (2 pages). cited by applicant .
Office Action in Canada Application No. 2819700 dated Mar. 6, 2015 (4 pages). cited by applicant .
Office Action in Canadian Application No. 2794669 dated Jan. 15, 2015 (4 pages). cited by applicant .
Office Action in Chilean Application No. 716-2011 dated Mar. 30, 2015( 6 pages). cited by applicant .
Office Action in Chinese Application No. 201080032541.2 dated Dec. 3, 2014 (3 pages). cited by applicant .
Office Action in Chinese Application No. 201180017181.3 dated Aug. 19, 2014 (7 pages). cited by applicant .
Office action in Chinese Application No. 20118017181.3 dated Decemeber 8, 2014 (9 pages). cited by applicant .
Office Action in Israel Application No. 237471 dated Mar. 10, 2015 (3 pages). cited by applicant .
Office Action in Mexican Application No. MX/a/2012/011171 dated Mar. 30, 2015 (6 pages). cited by applicant .
Office action in U.S. Appl. No. 11/353,597 dated Dec. 2, 2008. cited by applicant .
Office action in U.S. Appl. No. 13/925,078 dated Apr. 23, 2015 (7 pages). cited by applicant .
Office Action in Ukraine Application No. A 2012 12444 dated Jan. 27, 2015 (4 pages). cited by applicant .
Roman et al., J. Med. Chem. (2010), 53(21):7675-7681. cited by applicant .
Search and Examination Report in African Regional Intellectual Property Organization Application No. AP/P/2012/006543 dated Jan. 9, 2015 (4 pages). cited by applicant .
Search Report and Written Opinion for Singapore Application No. 2011086105 dated Apr. 30, 2014 (20 pages). cited by applicant .
Sofia, "Discovery of a beta-D-2'-Deoxy-2'-alpha-fluoro-2'-beta-C-methyluridine Nucleotide Prodrug (PSI-7977) for the Treament of Hepatitis C Virus," J. Med. Chem., (2010), 53. cited by applicant .
Stuyver et al., "Inhibition of the Subgenomic Hepatitis C Virus Replicon in Huh-7 Cells by 2'-Deoxy-2'- Fluorocytidine," Antimicrobial Agents and Chemotherapy, (2004), 48(2):651-654. cited by applicant .
Subsequent Substantive Examination Report for Philippines Application No. 1/2011/502433 dated Jan. 13, 2015 (1 page). cited by applicant .
Supplemntary Serarch Report in Singapore Application No. 201207206-2 dated Mar. 17, 2015, (7 pages). cited by applicant .
Zhou, Xiao-Jian, et al., "Safety and Pharmacokinetics of IDX184, a Liver-Targeted Nucleotide Polymerase Inhibitor of Hepatitis C Virus, in Healthy Subjects," Antimicrob. Agents & Chemother, (2011), 55(1 ):76-81. cited by applicant .
Zhu et al., "Design and synthesis of HCV agents with sequential triple inhibitory potentials," Bioorg. & Med. Chem. Lett., (2010), 20(17):5212-5216. cited by applicant.

Primary Examiner: Olson; Eric
Assistant Examiner: Miller; Dale R
Attorney, Agent or Firm: Sheppard Mullin Richter & Hampton LLP
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc